Dowling GP, Toomey S, Bredin P, Parker I, et al. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study). BMC Cancer 2024;24:91.
PMID: 38233810